Pre-Filled Syringes West Coast 2021

SMi Group 14 - 15 June 2021, San Diego, USA.
Following the success of the last event, the Pre-Filled Syringes West Coast conference is back to uncover the latest innovations in combination product development, device design, human factors engineering and drug product formulation to give a holistic overview of the industry and what we can expect for the future.

With the global market for prefilled syringes estimated to exceed $9.7bn by 2025, this year's agenda will encompass key drivers and hot topics of the industry including; updates to regulatory guidance from industry experts and regulatory bodies, case studies on device design and complex formulation, life cycle and control strategies, and innovations in connectivity and digital health.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more. PLUS, two interactive post conference workshops:

Workshop A: Connected devices and digital health: How to navigate the US FDA usability engineering requirements

Hosted by Shannon Clark, Principal, UserWise, Inc.

Workshop B: Postmarket safety reporting: The current regulatory environment with a global impact

Hosted by Khaudeja Bano, Sr. Medical Director, Abbott Molecular

Featured speakers

  • Brittney Pachucki, Device Engineer, AstraZeneca
  • Darin Zehrung, Global Program Leader, Medical Devices and Health Technologies, PATH
  • Jace Blackburn, Smart Device Engineer, Genentech
  • James P. Wabby, Executive Director, Regulatory Affairs - Device/Combination Products, Allergan
  • Jian Liu, Senior Scientist, Amgen
  • Khaudeja Bano, Senior, Medical Director, Abbott Diagnostics
  • Larry Atupem,  Sr Business Development Specialist, Zeon 
  • Maggie Reiff, Manager, Device Engineering, Pfizer
  • Mark DeStefano, Assoc. Dir. CPD Feasibility, New Technology and Prototyping Development, Teva Pharmaceuticals
  • Natalie Abts, Head of Human Factors Engineering, Genentech
  • Robert Ovadia, Engineer II, Genentech
  • Sarah Mollo, Combination Product Policy Analyst, FDA
  • Severine Duband, Global Category Manager, Nemera
  • Shannon Clark, Principal, UserWise, Inc.
  • Takuya Minezaki, Research Manager, Mitsubishi Gas Chemical Company, Inc.
  • Tina Rees, Associate Director - Human Factors, Ferring Pharmaceuticals
  • Tracy Hsu, Associate Director, Ionis Pharmaceuticals

Key reasons to attend

  • Engage in case study presentations from leading pharma and biotech companies on complex product formulation and optimising device design to aid delivery
  • Discuss show to optimise current processes to align with global regulatory updates
  • Delve into human factors engineering best practices
  • Uncover how industry is incorporating connectivity and digital health to optimise the user experience

Who should attend

Drug-delivery developers, Medical Device Engineers, Primary Packaging material designers, Secondary packagers, Smart device developers, Training device developers, Device-safety solution providers, Drug developers.

Early bird deadlines

  • Register by 31st March to save $200
  • Register by 30th April to save $100

For further information and to register, please visit:
http://www.prefilled-syringes-westcoast.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...